Barclays PLC increased its stake in ChromaDex Co. (NASDAQ:CDXC – Free Report) by 322.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,072 shares of the company’s stock after acquiring an additional 53,472 shares during the quarter. Barclays PLC’s holdings in ChromaDex were worth $256,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in CDXC. WINTON GROUP Ltd acquired a new position in ChromaDex in the second quarter valued at approximately $597,000. Bank of New York Mellon Corp lifted its stake in ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the period. BSW Wealth Partners acquired a new position in ChromaDex in the third quarter valued at approximately $324,000. BNP Paribas Financial Markets lifted its stake in ChromaDex by 1,885.7% in the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after buying an additional 69,582 shares during the period. Finally, State Street Corp increased its holdings in shares of ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares in the last quarter. 15.41% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.64% of the company’s stock.
ChromaDex Trading Up 0.5 %
ChromaDex (NASDAQ:CDXC – Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The business had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. On average, analysts predict that ChromaDex Co. will post 0.04 EPS for the current year.
Analyst Upgrades and Downgrades
CDXC has been the subject of several recent research reports. HC Wainwright boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Roth Mkm upped their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.
View Our Latest Stock Report on ChromaDex
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Stories
- Five stocks we like better than ChromaDex
- 3 Best Fintech Stocks for a Portfolio Boost
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What is a Dividend King?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Where to Find Earnings Call Transcripts
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChromaDex Co. (NASDAQ:CDXC – Free Report).
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.